Xin-Min Wang1 
,
Li Zhu1,
Ying-Jun Sun2,
Xiao-Ying Liu1,
Shu-Gang Dong1,
Jing Han2,
Jin-Ming Ji1
For correspondence:- Xin-Min Wang Email: wangxinminbb@163.com Tel:+865433282291
Accepted: 21 November 2018 Published: 27 December 2018
Citation: Wang X, Zhu L, Sun Y, Liu X, Dong S, Han J, et al. Effect of edaravone-urinary kallidinogenase combination treatment on acute cerebral infarction. Trop J Pharm Res 2018; 17(12):2477-2481 doi: 10.4314/tjpr.v17i12.25
© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the curative effect of edaravone in combination with urinary kallidinogenase in the treatment of acute cerebral infarction and its effect on serum high-sensitivity C-reactive protein (hs-CRP) and interleukin (IL).
Methods: One hundred and eighty patients with acute cerebral infarction (ACI) who were on admission from March 2015 to July 2016 participated in this study as research subjects. They were assigned to study group (59 patients) and control group (59 patients). Edaravone and conventional treatment were administered to the control group. In contrast, in addition to conventional treatment, the study group was given edaravone in combination with urinary kallidinogenase. Clinical effects, neurological function and serum IL-17 and hs-CRP levels in the two groups were determined.
Results: The overall response of the study group was significantly higher than that of the control group (p < 0.05). Scores in the National Institute of Health stroke scale (NIHSS) were reduced in both groups, and modified Barthel index (MBI) of both groups remarkably increased, when compared to values before treatment. Improvements in NIHSS score and MBI of the study group were higher than those of the control group (p < 0.05). Serum IL-17 and hs-CRP levels declined significantly in the two groups (p < 0.05), but post-treatment serum IL-17 and hs-CRP levels of the study group were significantly reduced, relative to control values (p < 0.05). There were no significant differences in incidence of adverse reactions between the two groups.
Conclusion: The use of edaravone in combination with urinary kallidinogenase in the treatment of ACI can significantly reduce serum IL-17 and hs-CRP levels without inducing severe adverse reactions.
Archives
News Updates
Fulltext in PDF